YZYing Zhang

Ying Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying Zhang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Zhaoyong Liu

    Department of Orthopedics, the First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.

    12 shared publications
  • Weiqing Lu

    Department of Radiotherapy, Cancer Hospital of Shantou University Medical College, No. 7 Raoping Road, Shantou, 515041, Guangdong, China

    10 shared publications
  • Zhaoyong Liu

    Department of Orthopaedics, First Affiliated Hospital of Shantou University Medical College, Shantou, China

    8 shared publications
  • Huancheng Guo

    Department of Orthopaedics, First Affiliated Hospital of Shantou University Medical College, Shantou, China

    7 shared publications
  • Yelong Chen

    Department of Orthopaedics, First Affiliated Hospital of Shantou University Medical College, Shantou, China

    7 shared publications
  • Chuangzhen Chen

    Department of Radiotherapy, Cancer Hospital of Shantou University Medical College, No. 7 Raoping Road, Shantou, Guangdong 515041, China;

    6 shared publications

Latest Publications

  • Open Access

    Tumor-suppressive tRNA-derived RNA fragment itRF-GlnCTG targets the RBMX-m6A axis to destabilize RCN1 mRNA in esophageal squamous cell carcinoma

    by Ying Zhang, Weiqing Lu, Lan Hu, Zikun Huang, Wenting Lin, Dan Guo, Zhaoyong Liu

    Transfer RNA-derived small RNAs (tsRNAs) have been recognized as important regulators in human cancers. However, the role of tumor-suppressive tsRNAs in esophageal squamous cell carcinoma (ESCC) has not been thoroughly characterized. This study sought to elucidate the function of tsRNA-Gln-i-0061 (itRF-GlnCTG) in ESCC and its underlying molecular mechanism. Bioinformatic approaches were employed to characterize the expression profile of tsRNAs in ESCC. Quantitative real-time PCR (qRT-PCR) and in situ hybridization (ISH) was applied to validate its expression levels in clinical samples. Functional assays, including proliferation and migration experiments, were conducted to detect the function of itRF-GlnCTG in ESCC. To identify downstream targets, RNA immunoprecipitation (RIP), biotin pull-down and mass spectrometry were performed. Additionally, the interaction between itRF-GlnCTG, the m6A reader RBMX, and reticulocalbin-1 (RCN1) mRNA was examined to uncover the regulatory mechanism. We identified itRF-GlnCTG as a downregulated tsRNA in ESCC tissues, and its elevated expression level correlated with better patient outcomes. Functionally, itRF-GlnCTG inhibited the growth, motility, and adhesion capabilities of ESCC cells. Mechanistically, itRF-GlnCTG acted as a molecular decoy by competitively binding to the m6A reader protein RBMX. This interaction impaired RBMX's SUMOylation, sequestered it in the cytoplasm, and thereby disrupted RBMX-mediated, m6A-dependent stabilization of RCN1 mRNA, leading to suppressed RCN1 expression. The combination of serum itRF-GlnCTG with CEA and CA199 showed high diagnostic efficacy for ESCC (AUC = 0.94). Our results uncover a novel tumor-suppressive function of itRF-GlnCTG in ESCC by targeting the RBMX-m6A axis to destabilize oncogenic RCN1 mRNA. This study underscores the diagnostic utility of itRF-GlnCTG and reveals a new tsRNA-m6A regulatory pathway in ESCC.

  • SNORA11B recruits SWI/SNF to suppress esophageal squamous cell carcinoma malignancy by promoting GPD1-mediated G3P accumulation and mitochondrial damage

    by Lan Hu, Weiqing Lu, Zikun Huang, Dongchen Liu, Xinrui Chen, Xinling Ma, Zhaoyong Liu, Ying Zhang

    Esophageal squamous cell carcinoma (ESCC) is a malignancy characterized by a poor prognosis, with dysregulated lipid metabolism and chromatin remodeling playing critical roles in its pathogenesis. Small nucleolar RNAs (snoRNAs) represent a conserved family of non-coding RNAs, primarily recognized for their role in directing post-transcriptional modifications of ribosomal RNAs (rRNAs), such as 2'-O-methylation and pseudouridylation. In this study, we identified a conserved H/ACA box snoRNA, SNORA11B, significantly downregulated in ESCC tissues and patient serum samples. Functionally, SNORA11B exerts tumor-suppressive effects by inhibiting proliferation and migration of ESCC cells and promoting apoptosis. Mechanistically, through RNA pulldown assays coupled with mass spectrometry, we identified SMARCA4, a core ATPase subunit of the SWI/SNF chromatin remodeling complex, as a direct interactor of SNORA11B. We further demonstrated that SNORA11B facilitates the recruitment of SMARCA4 to the GPD1 promoter region. This recruitment increases chromatin accessibility for the transcription factor C/EBPβ, thereby enabling transcriptional activation of GPD1. The subsequent upregulation of GPD1 leads to glycerol-3-phosphate (G3P) accumulation, which induces mitochondrial compromise, ultimately contributing to the suppression of tumor progression. Clinically, high expression of SNORA11B is significantly associated with favorable prognosis in ESCC patients. Moreover, its detectable stability in serum, together with a high area under the curve (AUC) value, highlights its promising utility as a novel diagnostic biomarker. Our findings reveal a non-canonical role of SNORA11B as an epigenetic regulator and underscore the SNORA11B/GPD1 axis as a promising diagnostic target for ESCC. SNORA11B recruits SMARCA4 to the GPD1 promoter, enhancing chromatin accessibility and facilitating C/EBPβ-mediated GPD1 transcription. This leads to mitochondrial dysfunction and suppresses esophageal squamous cell carcinoma progression.

  • CPSF2-mediated 3’ UTR truncation of MTERF3 drives mitochondrial dysfunction and osteosarcoma progression

    by Ying Zhang, Weiqing Lu, Zikun Huang, Lan Hu, Dan Guo, Wenting Lin, Zhaoyong Liu

    Alternative polyadenylation (APA), an important post-transcriptional regulatory mechanism, is aberrantly activated in cancer, but how APA functions in tumorigenesis remains elusive. We analyzed APA events in osteosarcoma (OS) tissues and identified 3' UTR alterations associated with both OS patient prognosis and gene expression changes involving loss of tumor-suppressive miRNA binding sites. In OS tumors, MTERF3 3' UTRs were recurrently shortened and MTERF3 mRNA levels were upregulated, and indicated poor prognosis. OS cells with shorter MTERF3 3' UTRs displayed elevated proliferation, migration, and invasion ability compared to the cells with control or longer MTERF3 3' UTR. Moreover, system correlation analysis revealed that CPSF2 is a candidate upstream regulator of MTERF3 3' UTR length. Mechanistically, CPSF2 favored use of the proximal poly (A) site in the 3' UTR of MTERF3, resulting in a short-3' UTR MTERF3 isoform that produced more MTERF3 protein due to loss of miR-182-5p binding sites. The shortened MTERF3 3' UTR disrupted competing endogenous RNA (ceRNA) cross-talk, resulting in downregulation of the tumor suppressor gene ADCY6. Collectively, these findings demonstrate that CPSF2-mediates MTERF3 3' UTR shortening through APA to promote OS tumor progression.

  • Open Access

    Biomolecular phase separation in tumorigenesis: from aberrant condensates to therapeutic vulnerabilities

    by Lan Hu, Zikun Huang, Zhaoyong Liu, Ying Zhang

    Biomolecular phase separation has emerged as a fundamental mechanism governing intracellular spatial organization and functional compartmentalization, and is increasingly recognized as a critical factor in tumor initiation and progression. Through multivalent molecular interactions, biomolecular phase separation contributes to the formation of condensates that mediate the assembly of membraneless organelles, coordination of signaling pathways, and transcriptional programs. Under physiological conditions, condensation contributes to the maintenance of gene expression homeostasis, stress adaptation, and metabolic balance. In cancer cells, however, biomolecular condensates (BMCs) often exhibit aberrant behavior, accompanied by alterations in their structure, components, and regulatory mechanisms. Such perturbations may disrupt cellular homeostasis and influence key biological processes including gene regulation, signal transduction, metabolic reprogramming, and immune responses, thereby modulating various cancer hallmarks. Although the mechanistic understanding of BMCs remains incomplete, their intrinsic plasticity and environmental sensitivity make them attractive therapeutic targets for cancer treatment. This review provides a comprehensive overview of the regulatory factors and functional mechanisms of BMCs in cancer biology, with a particular focus on their involvement in diverse cancer hallmarks. This review further summarizes emerging therapeutic strategies targeting condensation, aiming to inspire novel treatment opportunities.


  • Open Access

    Alternative cleavage and polyadenylation: key regulatory mechanisms in health and disease

    by Ying Zhang, Zikun Huang, Weiqing Lu, Zhaoyong Liu

    Alternative polyadenylation (APA) is a critical post-transcriptional regulatory mechanism that generates diverse mRNA isoforms by selecting different polyadenylation sites within pre-mRNAs, thereby modulating the length of the 3' untranslated region (3' UTR), thereby fine-tuning gene expression and protein synthesis. APA regulation involves conserved cis-acting elements, trans-acting factors, and key protein complexes such as CPSF and CSTF, influenced by the cellular context and various RNA-binding proteins. To address the complexity of APA, comprehensive methodologies and computational tools have been developed, leading to extensive APA databases with detailed biological annotations. Recent advancements in high-throughput sequencing and single-cell technologies have enhanced our understanding of APA's dynamic regulation across tissues and developmental stages, revealing its significant impact on cellular heterogeneity and disease progression. APA plays essential roles in numerous physiological processes, including neuronal homoeostasis, immune regulation, cardiovascular and vascular development, myogenesis, and metabolism. Dysregulation of APA is associated with a wide range of diseases, including neurodegenerative disorders, autoimmune conditions, cardiovascular diseases, metabolic syndromes, and genetic disorders. Clinically, targeting APA regulatory mechanisms offers promising opportunities for therapeutic interventions and the development of personalized medical strategies. This review highlights the pivotal role of APA in gene regulation and disease, emphasizing the need for continued research to unravel its complex mechanisms and leverage its potential in advancing precision medicine.


  • CPSF3 regulates alternative polyadenylation of CNIH2 to promote esophageal squamous cell carcinoma progression

    by Ying Zhang, Dongchen Liu, Dan Guo, Wenting Lin, Weiqing Lu, Lan Hu, Shuqin Chen, Chuangzhen Chen


  • Open Access

    Circ_0002669 promotes osteosarcoma tumorigenesis through directly binding to MYCBP and sponging miR-889-3p

    by Ying Zhang, Yizhou Zhan, Zhaoyong Liu, Huancheng Guo, Dongchen Liu, Chuangzhen Chen

    Circular RNAs (circRNAs) are a class of highly multifunctional single-stranded RNAs that play crucial roles in cancer progression, including osteosarcoma (OS). Circ_0002669, generated from the dedicator of cytokinesis (DOCK) gene, was highly expressed in OS tissues, and negatively correlated with OS patient survival. Elevated circ_0002669 promoted OS cell growth and invasion in vivo and in vitro. By biotin pulldown and mass spectroscopy, we found that circ_0002669 directly bound to MYCBP, a positive regulator of c-myc, to prevent MYCBP from ubiquitin-mediated proteasome degradation. In addition, circ_0002669 interacted with miR-889-3p and served as a miRNA sponge to increase the expression of MYCBP, as determined by luciferase assays and RNA immunoprecipitation. Functional rescue experiments indicated MYCBP acted as a key factor for circ_0002669- and miR-889-3p-regulated OS cell proliferation and migration. Increased expression of c-myc-associated genes, such as CCND1, c-Jun and CDK4, were found in circ_0002669- and MYCBP-overexpressing OS cells. Our data thus provide evidence that circ_0002669 promotes OS malignancy by protecting MYCBP from protein ubiquitination and degradation and blocking miR-889-3p-mediated inhibition of MYCBP expression.


  • Open Access

    A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity

    by Ying Zhang, Zhaoyong Liu, Zhigang Zhong, Yanchen Ji, Huancheng Guo, Weidong Wang, Chuangzhen Chen

    Background: Osteosarcoma (OS) is one of most commonly diagnosed bone cancer. Circular RNAs (circRNAs) are a class of highly stable non-coding RNA, the majority of which have not been characterized functionally. The underlying function and molecular mechanisms of circRNAs in OS have not been fully demonstrated. Method: Microarray analysis was performed to identify circRNAs that are differentially-expressed between OS and corresponding normal tissues. The biological function of circKEAP1 was confirmed in vitro and in vivo. Mass spectrometry and western blot assays were used to identify the circKEAP1-encoded protein KEAP1-259aa. The molecular mechanism of circKEAP1 was investigated by RNA sequencing and RNA immunoprecipitation analyses. Results: Here, we identified a tumor suppressor circKEAP1, originating from the back-splicing of exon2 of the KEAP1 gene. Clinically, circKEAP1 is downregulated in OS tumors and associated with better survival in cancer patients. N6-methyladenosine (m6A) at a specific adenosine leads to low expression of circKEAP1. Further analysis revealed that circKEAP1 contained a 777 nt long ORF and encoded a truncated protein KEAP1-259aa that reduces cell proliferation, invasion and tumorsphere formation of OS cells. Mechanistically, KEAP1-259aa bound to vimentin in the cytoplasm to promote vimentin proteasome degradation by interacting with the E3 ligase ARIH1. Moreover, circKEAP1 interacted with RIG-I to activate anti-tumor immunity via the IFN-γ pathway. Conclusion: Taken together, our findings characterize a tumor suppressor circKEAP1 as a key tumor suppressor regulating of OS cell stemness, proliferation and migration, providing potential therapeutic targets for treatment of OS.


  • Open Access

    Correction to: PITX1 suppresses osteosarcoma metastasis through exosomal LINC00662-mediated M2 macrophage polarization

    by Ying Zhang, Yelong Chen, Chuangzhen Chen, Huancheng Guo, Chunbin Zhou, Hu Wang, Zhaoyong Liu